Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus

Patients with type 2 diabetes mellitus have an increased risk of cardiovascular (CV) complications. Although hyperglycaemia contributes to the pathogenesis of atherosclerosis and heart failure in these patients, glucose-lowering strategies did not have a significant effect on reducing CV risk, parti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vladimir V. Salukhov, Tatiana Y. Demidova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	type 2 diabetes mellitus chronic heart failure cardiovascular mortality hyperglycemia insulin resistance risk factors empagliflozin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/df96db84249147979cbed089b1755da3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df96db84249147979cbed089b1755da3
record_format	dspace
spelling	oai:doaj.org-article:df96db84249147979cbed089b1755da32021-11-14T09:00:20ZEmpagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus2072-03512072-037810.14341/DM8216https://doaj.org/article/df96db84249147979cbed089b1755da32016-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/8216https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Patients with type 2 diabetes mellitus have an increased risk of cardiovascular (CV) complications. Although hyperglycaemia contributes to the pathogenesis of atherosclerosis and heart failure in these patients, glucose-lowering strategies did not have a significant effect on reducing CV risk, particularly in patients with a long duration of type 2 diabetes mellitus and prevalent CV disease (CVD). Sodium-glucose linked transporter-2 (SGLT2) inhibitors are a new class of anti-hyperglycaemic medications that increase glycaemic control via insulin-dependent mechanism of action associated with increased urinary glucose excretion.In this review, we present an analysis of the Empa-Reg Outcomes investigation, focussed on assessing the CV safety of empagliflozin, an inhibitor of SGLT2. We discuss the impressive results of trials that provide evidence on the cardiac and renal properties of empagliflozin. We present and analyse the current hypothesis on the mechanism of action of glucose-lowering medication, which has such a severe and complex impact on outcomes in patients with type 2 diabetes at high CV risk.Vladimir V. SalukhovTatiana Y. DemidovaEndocrinology Research Centrearticletype 2 diabetes mellituschronic heart failurecardiovascular mortalityhyperglycemiainsulin resistancerisk factorsempagliflozinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 6, Pp 494-510 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus chronic heart failure cardiovascular mortality hyperglycemia insulin resistance risk factors empagliflozin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus chronic heart failure cardiovascular mortality hyperglycemia insulin resistance risk factors empagliflozin Nutritional diseases. Deficiency diseases RC620-627 Vladimir V. Salukhov Tatiana Y. Demidova Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
description	Patients with type 2 diabetes mellitus have an increased risk of cardiovascular (CV) complications. Although hyperglycaemia contributes to the pathogenesis of atherosclerosis and heart failure in these patients, glucose-lowering strategies did not have a significant effect on reducing CV risk, particularly in patients with a long duration of type 2 diabetes mellitus and prevalent CV disease (CVD). Sodium-glucose linked transporter-2 (SGLT2) inhibitors are a new class of anti-hyperglycaemic medications that increase glycaemic control via insulin-dependent mechanism of action associated with increased urinary glucose excretion.In this review, we present an analysis of the Empa-Reg Outcomes investigation, focussed on assessing the CV safety of empagliflozin, an inhibitor of SGLT2. We discuss the impressive results of trials that provide evidence on the cardiac and renal properties of empagliflozin. We present and analyse the current hypothesis on the mechanism of action of glucose-lowering medication, which has such a severe and complex impact on outcomes in patients with type 2 diabetes at high CV risk.
format	article
author	Vladimir V. Salukhov Tatiana Y. Demidova
author_facet	Vladimir V. Salukhov Tatiana Y. Demidova
author_sort	Vladimir V. Salukhov
title	Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
title_short	Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
title_full	Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
title_fullStr	Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
title_full_unstemmed	Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
title_sort	empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/df96db84249147979cbed089b1755da3
work_keys_str_mv	AT vladimirvsalukhov empagliflozinasanewmanagementstrategyonoutcomesinpatientswithtype2diabetesmellitus AT tatianaydemidova empagliflozinasanewmanagementstrategyonoutcomesinpatientswithtype2diabetesmellitus
_version_	1718429559796269056

Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus

Ejemplares similares